| 1 |
Richards LG, Cramer SC. Advances in stroke: therapies targeting stroke recovery [J]. Stroke, 2021, 52(1): 348-350.
|
| 2 |
Anrather J, Iadecola C. Inflammation and stroke: an overview [J]. Neurotherapeutics, 2016, 13(4): 661-670.
|
| 3 |
Zhang SR, Phan TG, Sobey CG. Targeting the immune system for ischemic stroke [J]. Trends Pharmacol Sci, 2021, 42(2): 96-105.
|
| 4 |
Geng X, Wang Q, Lee H, et al. Remote ischemic postconditioning vs. physical exercise after stroke: an alternative rehabilitation strategy? [J]. Mol Neurobiol, 2021. Online ahead of print.
|
| 5 |
Geng X, Shen J, Li F, et al. Phosphoenolpyruvate carboxykinase (PCK) in the brain gluconeogenic pathway contributes to oxidative and lactic injury after stroke [J]. Mol Neurobiol, 2021, 58(5): 2309-2321.
|
| 6 |
Longa EZ, Weinstein PR, Carlson S, et al. Reversible middle cerebral artery occlusion without craniectomy in rats [J]. Stroke, 1989, 20(1): 84-91.
|
| 7 |
Xue J, Suarez JS, Minaai M, et al. HMGB1 as a therapeutic target in disease [J]. J Cell Physiol, 2021, 236(5): 3406-3419.
|
| 8 |
Wang C, Jiang J, Zhang X, et al. Inhibiting HMGB1 reduces cerebral ischemia reperfusion injury in diabetic mice [J]. Inflammation, 2016, 39(6): 1862-1870.
|
| 9 |
Ye Y, Zeng Z, Jin T, et al. The Role of high mobility group box 1 in ischemic stroke [J]. Front Cell Neurosci, 2019, 13: 127.
|
| 10 |
Zhang B, Shen J, Zhong Z, et al. PKM2 aggravates cerebral ischemia reperfusion-induced neuroinflammation via TLR4/MyD88/TRAF6 signaling pathway [J]. Neuroimmunomodulation, 2021, 28(1): 29-37.
|
| 11 |
Hatayama K, Chen RH, Hanson J, et al. High-mobility group box-1 and inter-alpha inhibitor proteins: In vitro binding and co-localization in cerebral cortex after hypoxic-ischemic injury [J]. FASEB J, 2021, 35(3): e21399.
|
| 12 |
Martinotti S, Patrone M, Ranzato E. Emerging roles for HMGB1 protein in immunity, inflammation, and cancer [J]. Immunotargets Ther, 2015, 4: 101-109.
|
| 13 |
Yanai H, Ban T, Taniguchi T. High-mobility group box family of proteins: Ligand and sensor for innate immunity [J]. Trends Immunol, 2012, 33(12): 633-640.
|
| 14 |
Gou X, Ying J, Yue Y, et al. The roles of high mobility group box 1 in cerebral ischemic injury [J]. Front Cell Neurosci, 2020, 14: 600280.
|
| 15 |
Wang Q, Zhao H, Gao Y, et al. Uric acid inhibits HMGB1-TLR4-NF-kappa B signaling to alleviate oxygen-glucose deprivation/reoxygenation injury of microglia [J]. Biochem Biophys Res Commun, 2021, 540: 22-28.
|
| 16 |
Lin CH, Chen HY, Wei KC. Role of HMGB1/TLR4 axis in ischemia/reperfusion-impaired extracellular glutamate clearance in primary astrocytes [J]. Cells, 2020, 9(12): 2585.
|
| 17 |
Wang J, Jiang Y, Zeng D, et al. Prognostic value of plasma HMGB1 in ischemic stroke patients with cerebral ischemia-reperfusion injury after intravenous thrombolysis [J]. J Stroke Cerebrovasc Dis, 2020, 29(9): 105055.
|
| 18 |
Watanabe H, Son M. The immune tolerance role of the HMGB1-RAGE axis [J]. Cells, 2021, 10(3): 564.
|
| 19 |
Wang Y, Li L, Deng S, et al. Ursolic acid ameliorates inflammation in cerebral ischemia and reperfusion injury possibly via high mobility group box 1/toll-like receptor 4/NF κB pathway [J]. Front Neurol, 2018, 9: 253.
|
| 20 |
Wang C, Jiang J, Zhang X, et al. Inhibiting HMGB1 reduces cerebral ischemia reperfusion injury in diabetic mice [J]. Inflammation, 2016, 39(6): 1862-1870.
|
| 21 |
Xiong X, Gu L, Wang Y, et al. Glycyrrhizin protects against focal cerebral ischemia via inhibition of T cell activity and HMGB1-mediated mechanisms [J]. J Neuroinflammation, 2016, 13(1): 241.
|